title: Expanding medicines for neurologic disorders on the WHO Model List.
abstract: The WHO Model List of Essential Medicines is a recommended formulary for high-priority diseases based on public health trends and epidemiology patterns. The biennial publication serves as a guide for countries, particularly low- and lower-middle-income countries, to develop their own national essential medicines list (EML), and many nongovernmental organizations base their medication supplies on the WHO EML. Over the last 40 years, WHO has expanded the EML in response to treatment gaps for infectious diseases, pediatrics, palliative care, and cancer. In contrast, neurotherapeutics are poorly represented on the Model List despite the global burden of neurologic disorders, which have continued to increase in the last decade. It is imperative that the neurology community advocate for more evidence-based neurologic medicines on the WHO EML. Equitable access to essential neurologic medicines is a crucial step toward reducing the treatment gap for high-burden neurologic disorders worldwide.
authors.affiliation: From the Community and Global Neurology Program, Department of Neurology, Columbia University Medical Center, New York, NY.
authors.forename: Kathryn
authors.initials: K
authors.lastname: Rimmer
authors.affiliation: From the Community and Global Neurology Program, Department of Neurology, Columbia University Medical Center, New York, NY.
authors.forename: Hiral
authors.initials: H
authors.lastname: Shah
authors.affiliation: From the Community and Global Neurology Program, Department of Neurology, Columbia University Medical Center, New York, NY. ktt2115@cumc.columbia.edu.
authors.forename: Kiran
authors.initials: K
authors.lastname: Thakur
mesh_terms: D018954:Drugs, Essential / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D008297:Male; D009422:Nervous System Diseases / Q000188:drug therapy*; D014944:World Health Organization
chemical_list: D018954:Drugs, Essential